

SOPHIRIS BIO INC.
Form 8-K
April 29, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

April 25, 2016

Date of Report (Date of earliest event reported)

**Sophiris
Bio Inc.**

(Exact
name of
registrant
as
specified
in its
charter)

British Columbia **001-36054** **98-1008712**
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)

1258 Prospect Street
92037
La Jolla, CA
(Address of principal executive offices) (Zip Code)

**Registrant's
telephone
number,
including
area
code: (858)
777-1760**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 25, 2016, Joseph L. Turner notified Sophiris Bio Inc. (the “Company”) that he would not be standing for re-election at the Company’s upcoming Annual General Meeting on May 27, 2016 for personal reasons unrelated to a disagreement with the Company. As such, Mr. Turner’s term on the Board of Directors will expire effective at the time of the Company’s Annual General Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sophiris Bio Inc.

Dated: April 29, 2016

By: /s/ Peter Slover
Peter Slover
*Chief Financial
Officer*